In conclusion, our meta-analysis did not demonstrate a significant role of the UGT2B17 deletion polymorphism and tumor susceptibility (OR = 1.118, 95%CI = 0.938–1.332, P>0.1). The gene discussed is UGT2B17; the disease is neoplasm.